Trump’s commissioner of the Food and Drug Administration, Dr. Martin Makary, has resigned. During Makary’s 13-month tenure, he attempted to split the difference between Health and Human Services Secretary Robert F. Kennedy Jr.’s Make America Healthy Again agenda and a more traditional approach to regulation, ultimately angering both camps. “Nobody was happy with what he did,” says Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School.
Shortly before his resignation, Makary had drawn the ire of President Trump for attempting to block the approval of fruit-flavored vapes, and anti-abortion groups for not placing harsher restrictions on the abortion pill mifepristone. But even before Makary took the helm, mass layoffs and the loss of scientific expertise had already thrown the FDA, which has oversight powers extending to more than a fifth of the U.S. economy, in turmoil.
The FDA’s deputy commissioner for food, Kyle Diamantis, will now assume Makary’s position in an acting capacity. Diamantas, a personal friend of Donald Trump Jr., does not have a background in medicine. The abrupt leadership shakeup is worrisome for the future of health and medicine in the United States, says Dr. Robert Steinbrook, the health research director at watchdog organization Public Citizen. “We need a strong public health agency,” he explains. “[But] when you pick them apart for particular theories and the idiosyncrasies of the Health and Human Services secretary, you destroy things which take years, if not decades, to rebuild.”
